Skip to main content
Psychopharmacology Bulletin › All Volumes & Issues › VOL 56 No. 2 › Psychopharmacotherapy of Alzheimer’s...
REVIEW ARTICLE

Psychopharmacotherapy of Alzheimer’s Disease—What Do We Have at Hand?

Ahmed Naguy, Saxby Pridmore, Anubhuti Singh, Awadhesh Solanki
Psychopharmacology Bulletin 56(2): 170-175, 2026/03/11; https://doi.org/10.64719/pb.16605

Abstract

~ Alzheimer’s disease (AD) is a devastating relentlessly progressive illness for which currently there is no definitive curative treatment. The mainstay of treatment remains symptomatic, though. Psychopharmacotherapy is only part of a multi-pronged package of care involving caregivers. Herein, authors would shed light on the main pharmacological options at hand.

Keywords

acetylcholinestrase inhibitors, alzheimer’s disease, complementary medicine, memantine, monoclonal antibodies, neuropsychiatric symptoms

Access This Article

Choose an access option below to view the full article.

Subscriber Access

If you or your institution has a subscription, log in to access this article.

Log In
Not yet subscribed? View subscription options

Purchase Article

Buy single-article access with a one-time purchase.

$30.00
Add to Cart

How to Cite

Ahmed Naguy, Saxby Pridmore, Anubhuti Singh, Awadhesh Solanki. Psychopharmacotherapy of Alzheimer’s Disease—What Do We Have at Hand?. Psychopharmacology Bulletin. 2026/03/11; 56(2):170-175. https://doi.org/10.64719/pb.16605